Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats

Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different dos...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental immunology Vol. 121; no. 1; pp. 151 - 156
Main Authors Sáez‐Torres, I., Espejo, C., Pérez, J. J., Acarín, N., Montalban, X., Martínez‐Cáceres, E. M.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.07.2000
Blackwell
Oxford University Press
Blackwell Science Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different doses and phases of the disease according to several treatment protocols, but we could not observe a consistent effect of peptide T ameliorating the disease. Lymph node cell proliferation and IL‐4 and interferon‐gamma production were also studied. We conclude that peptide T neither prevents nor ameliorates EAE in Lewis rats.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0009-9104
1365-2249
DOI:10.1046/j.1365-2249.2000.01259.x